QNRX News and Press, Quoin Pharmaceuticals Ltd. From 02/08/22

New York, NY - ( NewMediaWire ) - February 08, 2022 -  PCG Digital  - Emerging specialty pharma company, Quoin Pharmaceuticals (NASDAQ: QNRX), coined the phrase ‘Rare diseases are only rare if you don’t live with one’ to emphasize its own mission: to del...

- OrphanDC Gains Exclusive Rights to Commercialize QRX003 in Key Countries in Latin America - Fourth Distribution Partnership Established Since Going Public in October 2021 - Additional Territories in Discussion ASHBURN, Va., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Quoin Pharm...

If you’re looking for the best penny stocks to buy today , you’ve got your pick. Social media has become the new “investor lunch table” for gaining insight into stock market trends. With that can come plenty of noise and confusion, especially if you’re...

3 Penny Stocks to Watch as the Year Comes to an End While trading both penny stocks and blue chips has been difficult over the past two years, plenty of investors have been profitable. But, to fully understand why penny stocks are so volatile right now, we have to take a look at wha...

Reliance Global (NASDAQ:RELI) +85%. Aridis Pharmaceuticals (NASDAQ:ARDS) +72% after its antibody cocktail retains effectiveness against Omicron variant. Quoin Pharmaceuticals (NASDAQ:QNRX) +44%. Cassava Sciences (NASDAQ:SAVA) +40% Cassava Sciences, Biofrontera rise amid so...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re kicking off the day with a dive into the biggest pre-market stock movers for Tuesday! Source: ventdusud / Shutterstock.com Moving stocks this morning is Covid-19 antibody news, ear...

Quoin Pharmaceuticals, Inc., a wholly-owned subsidiary of Quoin Pharmaceuticals (NASDAQ:QNRX) has entered into an exclusive distribution agreement with Orpharm LLC for QRX003, Quoin’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease. Un...

ASHBURN, Va., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, ...

New York, New York--(Newsfile Corp. - December 14, 2021) - PCG Digital -- Drug development is complex, lengthy and expensive, and not without its risks. Bringing a drug to market takes years, with costs quickly running into hundreds of millions of dollars, and no promise of success at the end ...

New York, NY - ( NewMediaWire ) - November 16, 2021 - PCG Digital -- Following a successful merger, one firm is developing and commercializing therapies for rare skin conditions. Quoin Pharmaceuticals is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devast...